Bryan Garnier - Safecharge International Group (SCH) SAFECHARGE - BUY | 380p

Report

Bryan Garnier

Richard-Maxime Beaudoux

SAFECHARGE - BUY | 380p

SAFECHARGE - BUY | 380p(+50%)
Strong 2018 year-end

Trading update
Management appointment
We maintain our Buy recommendation and FV of 380p

28/11/2018 4 EN

Underlying

Safecharge International Group

SafeCharge International Group is a global provider of payments services, technologies and risk management solutions for online and mobile businesses. Co. has a diversified, blue chip client base and is a trusted payment partner for customers from various verticals. Co. has been Payment Card Industry Data Security Standard Level 1 certified since 2007 and Co. has operations in the United Kingdom, Guernsey, Cyprus, Bulgaria, Israel, Austria, Singapore and Hong Kong. Co. has four products: multi-channel payments, payment acceptance, card services and professional services.

See profile

GG00BYMK4250 Guernsey

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Richard-Maxime Beaudoux

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 18.42

November 25, 2019 November 25, 2019 14 EN

Bryan Garnier

SAFECHARGE: Consolidation now hitting SafeCharge | NEUTRAL vs. BUY | 380p(-11%)

SAFECHARGE - NEUTRAL vs. BUY | 380p(-11%) Consolidation now hitting SafeCharge A cash deal with a 25% premium to the undisturbed share price Strong strategic rationale for both partners Consolidation to continue

May 23, 2019 May 23, 2019 3 EN

On the shelves now: Consumer weekly #29

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we take a look at the April US CPI print. Happy reading!

4h / 37m 4h / 37m 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Alfen: waiting for growth in H2

Alfen has published Q1 2024 numbers (EUR117m top line, 8.2% EBITDA) below consensus, with the street expecting EUR143m and a 12.2% EBITDA. Elements communicated by management for H2 and reaffirmed FY24 guidance (EUR590-660m revenue, >11.3% EBITDA) suggest good visibility on the top line and robu

6h / 31m 6h / 31m 1 EN

Maria Vara

Maria Vara

ONWARD: Up-LIFT reveals ARC-EX extraordinary neurological potential vs SOC

The so-awaited full disclosure of the ARC-EX Up-LIFT pivotal study materialized yesterday with its publication in the top-tier scientific journal - Nature (access here). Whilst the top-line data reported in April 2023 already validated ARC-EX Therapy efficacy hitting 72% responder rate, the extende

7h / 25m 7h / 25m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SAFECHARGE - BUY | 380p

Monthly LMI Update Independent Investment Research

Feasibility Study Results in December to be a Catalyst for this Junior

SAFECHARGE: Consolidation now hitting SafeCharge | NEUTRAL vs. BUY | 380p(-11%)

On the shelves now: Consumer weekly #29

Alfen: waiting for growth in H2

ONWARD: Up-LIFT reveals ARC-EX extraordinary neurological potential vs SOC

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe